Saturday 17 October 2026 Export QSI’s income statement to Excel — free account

Quantum-Si Incorporated

Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 41.8%, EPS grew 31.3% and free cash flow grew 9.75%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.12 0.19 −14.50%

Follow QSI

Alert me

Market cap: $286.7M
P/E: 0.0×
Fwd P/E: −2.3×
Dividend yield: —
F-score: 2/9
Altman Z: 0.36
Beneish M: 2.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.56

Total sells 0.49

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	—	—	—	—	—	—
Sell	—	4	—	—	4	2	—	4	—	—	3	—

Insider Ownership 21.37%

Capital & Financial Ratios $m

Market Cap 286.74

Revenue 1.61

Net Income (98.52)

Free Cash Flow (93.69)

Net Debt (111.74)

Current Ratio 9.97

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.33)

P/S ratio 151.99

P/B ratio 1.35

Past 5Y EPS Growth —

This Y EPS Growth 15.61%

Next Y EPS Growth 17.27%

Next Y revenue growth (53.00%)

Next 5Y EPS Growth 19.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 76.87%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	258	210	163	112
Receivables	0	1	5	0
Inventory	4	4	3	2
Other	—	—	—	—
	266	218	176	119

	2023	2024	2025	Q'26
Payables	2	2	2	2
ST’ Debt	—	—	—	—
Other	—	—	1	—
	12	18	23	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(15.01%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	1	0	2
’24	0	1	1	1	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(18)	—	—	—
’25	(26)	(20)	(32)	(16)	(95)
’24	(23)	(19)	(23)	(23)	(88)
’23	(29)	(23)	(21)	(21)	(94)
’22	(23)	(26)	(22)	(20)	(91)
’21	(11)	(19)	(18)	(18)	(67)
’20	—	(17)	(7)	0	(33)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(19)	—	—	—
’25	(27)	(21)	(33)	(16)	(97)
’24	(24)	(20)	(24)	(24)	(92)
’23	(32)	(24)	(23)	(21)	(99)
’22	(26)	(29)	(24)	(23)	(101)
’21	(11)	(20)	(20)	(21)	(73)
’20	—	(18)	(7)	0	(33)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.10)	(0.11)	—	—	—
’25	(0.11)	(0.16)	(0.17)	(0.08)	(0.51)
’24	(0.14)	(0.16)	(0.18)	(0.23)	(0.71)
’23	(0.17)	(0.18)	(0.17)	(0.16)	(0.68)
’22	(0.25)	(0.23)	(0.23)	(0.24)	(0.95)
’21	(2.13)	(0.97)	(0.13)	(0.21)	(1.19)
’20	—	(1.53)	(1.60)	(0.24)	(6.84)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	9.88	5.33	1.72	1.12	0.61	0.95	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	11.88	25.00	8.31	3.90	4.14	5.77
People
People	Employees	—	—	—	—	2	153	196	159	143	145
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.01	0.02	0.02
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	1	3	2
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	45.10	52.32	47.33
	EBT	—	—	—	(36)	(37)	(95)	(132)	(96)	(101)	(101)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	(8,868.76)	(3,301.21)	(4,157.68)
	Net income	—	0	—	(36)	(37)	(95)	(132)	(96)	(101)	(101)
	Depreciation	—	—	—	1	1	1	12	4	(4)	(4)
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.01	0.02	0.01
	Earnings	—	—	—	(6.95)	(6.84)	(1.19)	(0.95)	(0.68)	(0.71)	(0.51)
	Cash flow	—	—	—	(5.97)	(6.08)	(0.84)	(0.65)	(0.67)	(0.61)	(0.48)
	Capex	—	—	—	(0.24)	(0.09)	(0.07)	(0.08)	(0.04)	(0.03)	(0.01)
	Free cash flow	—	—	—	(6.21)	(6.17)	(0.91)	(0.73)	(0.70)	(0.65)	(0.49)
	Book value	—	—	—	0.00	(29.82)	5.99	2.58	1.92	1.50	1.11
	Shares, m	—	—	—	5	5	80	139	141	143	198
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	—	265.10	126.43	89.30
	P/B	—	—	—	—	—	—	—	1.06	1.79	0.99
	EV/Sales	—	—	—	—	—	—	—	26.90	57.89	22.43
	EV/FCF	—	—	—	—	—	—	—	(0.29)	(1.92)	(0.56)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(31)	(33)	(67)	(91)	(94)	(88)	(95)
	Capex	—	—	—	(1)	0	(6)	(11)	(5)	(5)	(3)
	Free cash flow	—	—	—	(32)	(33)	(73)	(101)	(99)	(92)	(97)
Balance, $m
Balance, $m	Working capital	—	—	—	—	35	466	342	255	200	153
	Total debt	—	—	—	—	2	7	16	—	—	—
	Net debt	—	—	—	—	(35)	(471)	(351)	(258)	(210)	(163)
	Shareholders’ equity	—	—	—	—	(160)	477	359	272	215	220
Returns, %
Returns, %	ROA	—	—	—	0.00	(180.40)	(34.93)	(29.61)	(27.83)	(36.99)	(41.07)
	ROIC	—	—	—	0.00	0.00	(1,057.02)	(1,046.38)	(500.48)	(1,166.58)	(126.60)
	ROE	—	—	—	0.00	(23.08)	(59.87)	(31.69)	(30.45)	(41.48)	(46.52)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CV CapsoVision, Inc.	$343.2M	2.1×	— (loss-making)	+9.89% (above 0%: growing)	n/m	−84.44% (below 0%: shrinking)	51.36%	(208.07%)	Compare
RCEL Avita Medical Inc.	$333.1M	— (loss-making)	— (loss-making)	+17.83% (above 0%: growing)	n/m	+66.52% (above 0%: growing)	81.87%	(28.42%)	Compare
CLPT ClearPoint Neuro, Inc.	$294.1M	— (loss-making)	— (loss-making)	+18.07% (above 0%: growing)	n/m	−173.51% (below 0%: shrinking)	61.67%	(94.15%)	Compare
QSI Quantum-Si Incorporated	$286.7M	— (loss-making)	— (loss-making)	−41.79% (below 0%: shrinking)	n/m	+9.75% (above 0%: growing)	50.00%	(7,450.29%)
INFU InfuSystems Holdings, Inc.	$277.2M	31.7×	21.7×	+2.59% (above 0%: growing)	+33.33% (above 0%: growing)	−66.54% (below 0%: shrinking)	57.98%	11.24%	Compare
TMCI Treace Medical Concepts, Inc.	$267.9M	— (loss-making)	— (loss-making)	−4.24% (below 0%: shrinking)	n/m	+11.74% (above 0%: growing)	78.47%	(32.96%)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
Median of peers	$272.6M	2.9×	—	+2.16%	—	−53.69%	70.07%	(90.09%)

All 149 Medical Devices stocks →

Quantum-Si Incorporated (QSI) key facts

Concern: Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024.
Quantum-Si Incorporated (QSI) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, QSI traded at $1.12, a market capitalization of $286.7 million.
Return on equity was −46.5% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.36 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.